摘要
目的探讨给予晚期结肠癌患者贝伐珠单抗与卡培他滨药物联合治疗的效果。方法纳入2019年1月至2023年12月宁波大学附属第一医院收治的85例晚期结肠癌患者进行分组观察,以随机数字表法将85例患者分为单药组(42例)及联合用药组(43例),单药组患者一线化疗后采取卡培他滨片单药维持治疗,联合用药组患者采取贝伐珠单抗联合卡培他滨治疗,观察两组治疗总有效率、不良反应、治疗前后血清癌胚抗原(CEA)、糖类抗原199(CA199)、Karnofsky功能状态评分(KPS)与美国东部肿瘤协作组体力状态评分(ECOG评分)。结果联合用药组患者治疗总有效率(88.37%)高于单药组(69.05%)(χ^(2)=4.753,P<0.05);两组不良反应症状较轻,经对症处理后均缓解,联合用药组患者不良反应发生率(25.58%)与单药组(28.57%)相当(χ^(2)=0.096,P>0.05);联合用药组患者治疗后的血清癌胚抗原(CEA)、糖类抗原199(CA199)分别为(9.50±2.02)ng·mL^(-1)、(8.94±0.45)U·mL^(-1),均低于单药组((15.45±2.68)ng·mL^(-1)、(9.45±0.23)U·mL^(-1)),(t=11.577,6.555,均P<0.05);联合用药组患者治疗后的KPS与ECOG评分分别为(69.73±4.02)分、(1.18±0.17)分,均优于单药组((62.36±3.85)分、(1.42±0.20)分),(t=8.629,5.966,均P<0.05)。结论贝伐珠单抗与卡培他滨联合治疗晚期结肠癌有助于降低血清肿瘤标志物水平,改善体力及生活质量。
Objective To investigate the efficacy of bevacizumab combined with capecitabine in the treatment of advanced colon cancer.Methods A total of 85 patients with advanced colon cancer admitted to the First Affiliated Hospital of Ningbo University from January 2019 to December 2023 were enrolled in this study and divided into the monotherapy group(n=42)and the combination therapy group(n=43)using a random number table method.Patients in the monotherapy group received capecitabine monotherapy after first-line chemotherapy treatment while those in the combination therapy group received bevacizumab combined with capecitabine treatment.The total effective rate of treatment,adverse reactions to treatment,serum carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),Karnofsky Performance Status(KPS)score,and Eastern Cooperative Oncology Group(ECOG)physical status score before and after treatment were recorded and compared between the two groups.Results The total effective rate of the combined drug group was higher than that of the single drug group(88.37%vs 69.05%,χ^(2)=4.753,P<0.05).The incidence of adverse reactions in the combination therapy group was similar to that in the monotherapy group(25.58%vs 28.57%,χ^(2)=0.096,P>0.05).Serum levels of carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199)after treatment in the combination therapy group were(9.50±2.02)ng·mL^(-1) and(8.94±0.45)U·mL^(-1),respectively,which were lower than those((15.45±2.68)ng·mL^(-1) and(9.45±0.23)U·mL^(-1))in the monotherapy group(t=11.577,6.555,both P<0.05).The KPS and ECOG were(69.73±4.02)and(1.18±0.17)in the combination therapy group,which were better than those of((62.36±3.85)and(1.42±0.20))in the monotherapy group(t=8.629,5.966,both P<0.05).Conclusion The combination of bevacizumab and capecitabine has a significant therapeutic effect on advanced colon cancer.It can decrease serum tumor marker levels and improve physical fitness and quality of life.
作者
武鸿彪
刘东方
刘烨磊
Wu Hong-biao;Liu Dong-fang;Liu Ye-lei(Department of Colorectal and Anorectal Surgery,the First Affiliated Hospital of Ningbo University,Ningbo 315000,China)
出处
《中国药物应用与监测》
CAS
2024年第3期208-211,共4页
Chinese Journal of Drug Application and Monitoring
